Cargando…

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol

Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evol...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallard, Joris, Hucteau, Elyse, Schott, Roland, Petit, Thierry, Demarchi, Martin, Belletier, Christine, Ben Abdelghani, Meher, Carinato, Hélène, Chiappa, Pascale, Fischbach, Cathie, Kalish-Weindling, Michal, Bousinière, Audren, Dufour, Stéphane, Favret, Fabrice, Pivot, Xavier, Hureau, Thomas J., Pagano, Allan F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438727/
https://www.ncbi.nlm.nih.gov/pubmed/32903594
http://dx.doi.org/10.3389/fonc.2020.01304
_version_ 1783572845991821312
author Mallard, Joris
Hucteau, Elyse
Schott, Roland
Petit, Thierry
Demarchi, Martin
Belletier, Christine
Ben Abdelghani, Meher
Carinato, Hélène
Chiappa, Pascale
Fischbach, Cathie
Kalish-Weindling, Michal
Bousinière, Audren
Dufour, Stéphane
Favret, Fabrice
Pivot, Xavier
Hureau, Thomas J.
Pagano, Allan F.
author_facet Mallard, Joris
Hucteau, Elyse
Schott, Roland
Petit, Thierry
Demarchi, Martin
Belletier, Christine
Ben Abdelghani, Meher
Carinato, Hélène
Chiappa, Pascale
Fischbach, Cathie
Kalish-Weindling, Michal
Bousinière, Audren
Dufour, Stéphane
Favret, Fabrice
Pivot, Xavier
Hureau, Thomas J.
Pagano, Allan F.
author_sort Mallard, Joris
collection PubMed
description Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal). Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed. Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide insightful information about two factors that may have substantial interaction but require further investigation. Trial registration: This prospective study has been registered at ClinicalTrials.gov (NCT03956641), May, 2019.
format Online
Article
Text
id pubmed-7438727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74387272020-09-03 Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol Mallard, Joris Hucteau, Elyse Schott, Roland Petit, Thierry Demarchi, Martin Belletier, Christine Ben Abdelghani, Meher Carinato, Hélène Chiappa, Pascale Fischbach, Cathie Kalish-Weindling, Michal Bousinière, Audren Dufour, Stéphane Favret, Fabrice Pivot, Xavier Hureau, Thomas J. Pagano, Allan F. Front Oncol Oncology Background: Cancer cachexia and exacerbated fatigue represent two hallmarks in cancer patients, negatively impacting their exercise tolerance and ultimately their quality of life. However, the characterization of patients' physical status and exercise tolerance and, most importantly, their evolution throughout cancer treatment may represent the first step in efficiently counteracting their development with prescribed and tailored exercise training. In this context, the aim of the PROTECT-01 study will be to investigate the evolution of physical status, from diagnosis to the end of first-line treatment, of patients with one of the three most common cancers (i.e., lung, breast, and colorectal). Methods: The PROTECT-01 cohort study will include 300 patients equally divided between lung, breast and colorectal cancer. Patients will perform a series of assessments at three visits throughout the treatment: (1) between the date of diagnosis and the start of treatment, (2) 8 weeks after the start of treatment, and (3) after the completion of first-line treatment or at the 6-months mark, whichever occurs first. For each of the three visits, subjective and objective fatigue, maximal voluntary force, body composition, cachexia, physical activity level, quality of life, respiratory function, overall physical performance, and exercise tolerance will be assessed. Discussion: The present study is aimed at identifying the nature and severity of maladaptation related to exercise intolerance in the three most common cancers. Therefore, our results should contribute to the delineation of the needs of each group of patients and to the determination of the most valuable exercise interventions in order to counteract these maladaptations. This descriptive and comprehensive approach is a prerequisite in order to elaborate, through future interventional research projects, tailored exercise strategies to counteract specific symptoms that are potentially cancer type-dependent and, in fine, to improve the health and quality of life of cancer patients. Moreover, our concomitant focus on fatigue and cachexia will provide insightful information about two factors that may have substantial interaction but require further investigation. Trial registration: This prospective study has been registered at ClinicalTrials.gov (NCT03956641), May, 2019. Frontiers Media S.A. 2020-08-07 /pmc/articles/PMC7438727/ /pubmed/32903594 http://dx.doi.org/10.3389/fonc.2020.01304 Text en Copyright © 2020 Mallard, Hucteau, Schott, Petit, Demarchi, Belletier, Ben Abdelghani, Carinato, Chiappa, Fischbach, Kalish-Weindling, Bousinière, Dufour, Favret, Pivot, Hureau and Pagano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Mallard, Joris
Hucteau, Elyse
Schott, Roland
Petit, Thierry
Demarchi, Martin
Belletier, Christine
Ben Abdelghani, Meher
Carinato, Hélène
Chiappa, Pascale
Fischbach, Cathie
Kalish-Weindling, Michal
Bousinière, Audren
Dufour, Stéphane
Favret, Fabrice
Pivot, Xavier
Hureau, Thomas J.
Pagano, Allan F.
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title_full Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title_fullStr Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title_full_unstemmed Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title_short Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol
title_sort evolution of physical status from diagnosis to the end of first-line treatment in breast, lung, and colorectal cancer patients: the protect-01 cohort study protocol
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438727/
https://www.ncbi.nlm.nih.gov/pubmed/32903594
http://dx.doi.org/10.3389/fonc.2020.01304
work_keys_str_mv AT mallardjoris evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT hucteauelyse evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT schottroland evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT petitthierry evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT demarchimartin evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT belletierchristine evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT benabdelghanimeher evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT carinatohelene evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT chiappapascale evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT fischbachcathie evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT kalishweindlingmichal evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT bousiniereaudren evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT dufourstephane evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT favretfabrice evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT pivotxavier evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT hureauthomasj evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol
AT paganoallanf evolutionofphysicalstatusfromdiagnosistotheendoffirstlinetreatmentinbreastlungandcolorectalcancerpatientstheprotect01cohortstudyprotocol